-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation and inflammation without secondary causes and heavy alcohol consumption
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation and inflammation without secondary causes and heavy alcohol consumption
Insulin resistance is a major component of the metabolic syndrome, an important feature of T2D and obesity, and a key causative factor in NASH
These insights have led to the search for new potential treatments as our understanding of the pathophysiology of NASH continues to grow
Objective: To review the research on GLP-1RAs related to NASH treatment
Methods: PubMed was searched and the results were sorted
RESULTS: Large trials using GLP-1RAs in T2D demonstrated highly effective glucose lowering, weight loss, and, in some cases, reductions in cardiovascular events and improvements in hepatic transaminases
Figure 1 Overview of the physiological effects of the GLP-1 receptor agonist GLP-1RA (drug-specific)
Figure 1 Overview of the physiological effects of the GLP-1 receptor agonist GLP-1RA (drug-specific)Table: Review of phase III international CVOTS using GLP-1RAs in patients with T2D and high cardiovascular risk
Table: Review of phase III international CVOTS using GLP-1RAs in patients with T2D and high cardiovascular riskConclusions: These studies support the use of GLP-1RAs to improve the underlying metabolic dysfunction observed in NASH and recommend further long-term phase III trials
These studies support the use of GLP-1RAs to improve the underlying metabolic dysfunction observed in NASH and recommend further long-term phase III trials
Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Leave a comment here